Novan Therapeutics To Present Antiviral Preclinical Results Of Nitric Oxide-Releasing Drug Candidates For The Treatment Of Papillomavirus

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DURHAM, N.C.--(BUSINESS WIRE)--Novan Therapeutics, a clinical stage biotech company focused on advancing nitric oxide therapies, announced today that antiviral data from a preclinical animal study has been accepted for presentation at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 5-9, 2014, in Washington, DC.

Presentation Number V-1822a: “Antiviral Efficacy of Nitric Oxide-Releasing Drug Candidates In Vivo Utilizing the Cottontail Rabbit Papillomavirus Model,” K. Coggan, K. Balogh, S. Hollenbach, N. Christensen, and N. Stask

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC